ESMO-IASLC Best Abstracts
Invited Discussant LBA1 and LBA3
Date
11 Apr 2019Session
ESMO-IASLC Best AbstractsPresenters
Luis Paz-AresAuthors
L. Paz-AresAuthor affiliations
- Medical Oncology Dept., University Hospital 12 De Octubre, 28041 - Madrid/ES
Resources
Resources from the same session
542 - Final Analysis of the Phase 3 KEYNOTE-042 Study: Pembrolizumab (Pembro) Versus Platinum-Based Chemotherapy (Chemo) as First-Line Therapy for Patients (Pts) With PD-L1–Positive Locally Advanced/Metastatic NSCLC
Presenter: Tony S.K. Mok
Session: ESMO-IASLC Best Abstracts
Resources:
Abstract
Slides
Webcast
466 - Safety and Efficacy of Pembrolizumab (Pembro) Monotherapy in Elderly Patients (Pts) With PD-L1–positive Advanced NSCLC: Pooled Analysis from KEYNOTE-010, -024, and -042
Presenter: Kaname Nosaki
Session: ESMO-IASLC Best Abstracts
Resources:
Abstract
Slides
Webcast
683 - Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): results from the double-blind, randomized phase 3 CheckMate 451 study
Presenter: Taofeek Owonikoko
Session: ESMO-IASLC Best Abstracts
Resources:
Abstract
Slides
Webcast
376 - Efficacy and safety of first-line durvalumab (D) ± tremelimumab (T) vs platinum-based chemotherapy (CT) based on clinical characteristics in patients with metastatic (m) NSCLC: results from MYSTIC
Presenter: Byoung Chul Cho
Session: ESMO-IASLC Best Abstracts
Resources:
Abstract
Slides
Webcast
Invited Discussant 102O and 103O
Presenter: Sanjay Popat
Session: ESMO-IASLC Best Abstracts
Resources:
Slides
Webcast
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
-
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.